ArticleJournal of translational medicine2011
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients.
Article in Journal of translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Magnetic-Assisted Manipulation of Rare Blood Cells for Diagnosis: A Systematic Review.Biotechnology and bioengineering · 2025Pooled it
- Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis.Scientific reports · 2017Pooled it
- Diagnostic and Prognostic Utility of Cell-Surface Vimentin Positive Circulating Tumor Cells in Breast Cancer Using an Automated Negative Selection Platform.Diseases (Basel, Switzerland) · 2026Article
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- Circulating Tumor Cells: Emerging Frontiers in Cancer Technology.Expert reviews in molecular medicine · 2026Review
- Circulating tumor cells as biomarkers in melanoma: techniques, challenges, and clinical applications.Frontiers in cell and developmental biology · 2026Review
- A fixation-compatible protocol for intracellular and surface marker-based detection of circulating tumor cells in hepatocellular carcinoma.Scientific reports · 2025Article
- A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer.Molecular oncology · 2025Article
- Development of PowerMag System II for Isolation of Circulating Tumor Cells with Improved Purity.Biomedicines · 2025Article
- Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).Oncology letters · 2025Review
- Design of buffer property for the new enrichment method of circulating tumor cell based on immunomagnetic-negative separation.Computational and structural biotechnology journal · 2024Article
- The integrated on-chip isolation and detection of circulating tumour cells.Sensors & diagnostics · 2024Review
- Clinical significance of genomic sequencing of circulating tumour cells (CTCs) in cancer.The journal of liquid biopsy · 2024Review
- Dissemination of Circulating Tumor Cells in Breast and Prostate Cancer: Implications for Early Detection.Endocrinology · 2024Review
- Circulating tumour cell clusters: isolation, biological significance and therapeutic implications.BMJ oncology · 2024Review
- Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.Scientific reports · 2023Article
- CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.International journal of molecular sciences · 2023Review
- Review
- Circulating tumor cell isolation for cancer diagnosis and prognosis.EBioMedicine · 2022Review
- Detection of circulating tumor cells: opportunities and challenges.Biomarker research · 2022Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA limitation of positive selection strategies to enrich for circulating tumor cells (CTCs) is that there might be CTCs with insufficient expression of the surface target marker which may be missed by the procedure. We optimized a method for enrichment, subsequent detection and characterization of CTCs based on depletion of the leukocyte fraction.
methodsThe 2-step protocol was developed for processing 20 mL blood and based on red blood cell lysis followed by leukocyte depletion. The remaining material was stained with the epithelial markers EpCAM and cytokeratin (CK) 7/8 or for the melanoma marker HMW-MAA/MCSP. CTCs were detected by flow cytometry. CTCs enriched from blood of patients with carcinoma were defined as EpCAM+CK+CD45-. CTCs enriched from blood of patients with melanoma were defined as MCSP+CD45-. One-hundred-sixteen consecutive blood samples from 70 patients with metastatic carcinomas (n = 48) or metastatic melanoma (n = 22) were analyzed.
resultsCTCs were detected in 47 of 84 blood samples (56%) drawn from carcinoma patients, and in 17 of 32 samples (53%) from melanoma patients. CD45-EpCAM-CK+ was detected in pleural effusion specimens, as well as in peripheral blood samples of patients with NSCLC. EpCAM-CK+ cells have been successfully cultured and passaged longer than six months suggesting their neoplastic origin. This was confirmed by CGH. By defining CTCs in carcinoma patients as CD45-CK+ and/or EpCAM+, the detection rate increased to 73% (61/84).
conclusionEnriching CTCs using CD45 depletion allowed for detection of epithelial cancer cells not displaying the classical phenotype. This potentially leads to a more accurate estimation of the number of CTCs. If detection of CTCs without a classical epithelial phenotype has clinical relevance need to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.